Research Progress of Cancer Stem Cells in Uveal Melanoma

References

• Hu DN, Yu GP, McCormick SA, Schneider S, Finger PT. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol. 2005;140(4):612.e1–612.e8. doi:10.1016/j.ajo.2005.05.034
   Web of Science ®Google Scholar
• Houtzagers LE, Wierenga APA, Ruys AAM, Luyten GPM, Jager MJ. Iris colour and the risk of developing uveal melanoma. Int J Mol Sci. 2020;21(19):7172. doi:10.3390/ijms21197172
   PubMed Web of Science ®Google Scholar
• Ghazawi FM, Darwich R, Le M, et al. Uveal melanoma incidence trends in Canada: a national comprehensive population-based study. Br J Ophthalmol. 2019;103(12):1872–1876. doi:10.1136/bjophthalmol-2018-31296630819691
   PubMed Web of Science ®Google Scholar
• Aronow ME, Topham AK, Singh AD. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973–2013). Ocul Oncol Pathol. 2018;4(3):145–151. doi:10.1159/00048064029765944
   PubMed Web of Science ®Google Scholar
• Kaštelan S, Antunica AG, Oresković LB, et al. Immunotherapy for uveal melanoma - current knowledge and perspectives. Curr Med Chem. 2019. doi:10.2174/0929867326666190704141444
   Web of Science ®Google Scholar
• Komatsubara KM, Carvajal RD. Immunotherapy for the treatment of uveal melanoma: current status and emerging therapies. Curr Oncol Rep. 2017;19(7):45. doi:10.1007/s11912-017-0606-528508938
   PubMed Web of Science ®Google Scholar
• Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells - Perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006;66(19):9339–9344. doi:10.1158/0008-5472.CAN-06-312616990346
   PubMedGoogle Scholar
• Murphy GF, Wilson BJ, Girouard SD, Frank NY, Frank MH. Stem cells and targeted approaches to melanoma cure. Mol Aspects Med. 2014;39(1):33–49. doi:10.1016/j.mam.2013.10.00324145241
   PubMedGoogle Scholar
• Yu Y, Ramena G, Elble RC. The role of cancer stem cells in relapse of solid tumors. Front Biosci (Elite Ed). 2012;4(2):1528–1541. doi:10.2741/47822201973
   PubMedGoogle Scholar
• Prasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer. 2017;16(1). doi:10.1186/s12943-017-0600-4
   PubMedGoogle Scholar
• Jin B, Zhang P, Zou H, et al. Verification of EZH2 as a druggable target in metastatic uveal melanoma. Mol Cancer. 2020;19(1):1–15. doi:10.1186/s12943-020-01173-x31901224
   PubMed Web of Science ®Google Scholar
• Zhou J, Liu S, Wang Y, et al. Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma. Mol Cancer. 2019;18(1):159. doi:10.1186/s12943-019-1068-131718679
   PubMed Web of Science ®Google Scholar
• Djirackor L, Kalirai H, Coupland SE, Petrovski G. CD166high uveal melanoma cells represent a subpopulation with enhanced migratory capacity. Investig Ophthalmol Vis Sci. 2019;60(7):2696–2704. doi:10.1167/iovs.18-2643131242292
   PubMed Web of Science ®Google Scholar
• Kalirai H, Damato BE, Coupland SE. Uveal melanoma cell lines contain stem-like cells that self-renew, produce differentiated progeny, and survive chemotherapy. Investig Ophthalmol Vis Sci. 2011;52(11):8458–8466. doi:10.1167/iovs.11-737921896849
   PubMed Web of Science ®Google Scholar
• Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64(20):7205–7209. doi:10.1158/0008-5472.CAN-04-175015492234
   PubMed Web of Science ®Google Scholar
• Chang SH, Worley LA, Onken MD, Harbour JW. Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res. 2008;18(3):191–200. doi:10.1097/CMR.0b013e328300527018477893
   PubMed Web of Science ®Google Scholar
• Matatall KA, Agapova OA, Onken MD, et al. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer. 2013;13(1). doi:10.1186/1471-2407-13-371.
   PubMedGoogle Scholar
• Kuznetsov JN, Aguero TH, Owens DA, et al. BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers. Sci Adv. 2019;5(9):eaax1738. doi:10.1126/sciadv.aax173831555735
   PubMed Web of Science ®Google Scholar
• Herold-Mende C, Mock A. Microenvironment and brain tumor stem cell maintenance: impact of the niche. Anticancer Agents Med Chem. 2014;14(8):1065–1074. doi:10.2174/187152061466614082510363625175691
   PubMed Web of Science ®Google Scholar
• Leon G, MacDonagh L, Finn SP, Cuffe S, Barr MP. Cancer stem cells in drug resistant lung cancer: targeting cell surface markers and signaling pathways. Pharmacol Ther. 2016;158:71–90. doi:10.1016/j.pharmthera.2015.12.00126706243
   PubMed Web of Science ®Google Scholar
• Peiris-Pagès M, Martinez-Outschoorn UE, Pestell RG, Sotgia F, Lisanti MP. Cancer stem cell metabolism. Breast Cancer Res. 2016;18(1):55. doi:10.1186/s13058-016-0712-627220421
   PubMedGoogle Scholar
• Tirosh I, Venteicher AS, Hebert C, et al. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature. 2016;539(7628):309–313. doi:10.1038/nature2012327806376
   PubMed Web of Science ®Google Scholar
• Thill M, Berna MJ, Grierson R, et al. Expression of CD133 and other putative stem cell markers in uveal melanoma. Melanoma Res. 2011;21(5):405–416. doi:10.1097/CMR.0b013e328348db1021900792
   PubMed Web of Science ®Google Scholar
• Grossniklaus HE, Zhang Q, You S, et al. Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth patterns. Hum Pathol. 2016;57:165–175. doi:10.1016/j.humpath.2016.07.01227476775
   PubMed Web of Science ®Google Scholar
• Djirackor L, Shakir D, Kalirai H, Petrovski G, Coupland SE. Nestin expression in primary and metastatic uveal melanoma – possible biomarker for high-risk uveal melanoma. Acta Ophthalmol. 2018;96(5):503–509. doi:10.1111/aos.1364529338117
   PubMed Web of Science ®Google Scholar
• Valyi-Nagy K, Kormos B, Ali M, Shukla D, Valyi-Nagy T. Stem cell marker CD271 is expressed by vasculogenic mimicryforming uveal melanoma cells in three-dimensional cultures. Mol Vis. 2012;18:(March):588–592.
   Web of Science ®Google Scholar
• Bergeron MA, Champagne S, Gaudreault M, Deschambeault A, Landreville S. Repression of genes involved in melanocyte differentiation in uveal melanoma. Mol Vis. 2012;18:1813–1822.22815634
   PubMed Web of Science ®Google Scholar
• Radberger P, Radberger A, Vladimir JNB, Seregard S, Economou MA. JARID1B protein expression and prognostic implications in uveal melanoma. Investig Ophthalmol Vis Sci. 2012;53(8):4442–4449. doi:10.1167/iovs.11-929622669717
   PubMed Web of Science ®Google Scholar
• Roudi R, Korourian A, Shariftabrizi A, Madjd Z. Differential expression of cancer stem cell markers ALDH1 and CD133 in various lung cancer subtypes. Cancer Invest. 2015;33(7):294–302. doi:10.3109/07357907.2015.103486926046383
   PubMed Web of Science ®Google Scholar
• Jang JW, Song Y, Kim SH, Kim J, Seo HR. Potential mechanisms of CD133 in cancer stem cells. Life Sci. 2017;184:25–29. doi:10.1016/j.lfs.2017.07.00828697984
   PubMed Web of Science ®Google Scholar
• Madjd Z, Erfani E, Gheytanchi E, et al. Expression of CD133 cancer stem cell marker in melanoma: a systematic review and meta-analysis. Int J Biol Markers. 2016;31(2):e118–e125. doi:10.5301/jbm.500020927102864
   PubMed Web of Science ®Google Scholar
• Lunter PC, van Kilsdonk JWJ, van Beek H, et al. Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res. 2005;65(19):8801–8808. doi:10.1158/0008-5472.CAN-05-037816204050
   PubMed Web of Science ®Google Scholar
• Boiko AD, Razorenova OV, Van De Rijn M, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010;466(7302):133–137. doi:10.1038/nature0916120596026
   PubMed Web of Science ®Google Scholar
• Prasmickaite L, Engesæter B, Skrbo N, et al. Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS One. 2010;5(5):e10731. doi:10.1371/journal.pone.001073120505780
   PubMed Web of Science ®Google Scholar
• Sarvi S, Crispin R, Lu Y, et al. ALDH1 bio-activates nifuroxazide to eradicate ALDH high melanoma-initiating cells. Cell Chem Biol. 2018;25(12):1456–1469.e6. doi:10.1016/j.chembiol.2018.09.00530293938
   PubMed Web of Science ®Google Scholar
• Yue L, Huang ZM, Fong S, et al. Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma. Melanoma Res. 2015;25(2):138–148. doi:10.1097/CMR.000000000000014425643237
   PubMed Web of Science ®Google Scholar
• Santini R, Pietrobono S, Pandolfi S, et al. SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells. Oncogene. 2014;33(38):4697–4708. doi:10.1038/onc.2014.7124681955
   PubMed Web of Science ®Google Scholar
• Schaefer SM, Segalada C, Cheng PF, et al. Sox2 is dispensable for primary melanoma and metastasis formation. Oncogene. 2017;36(31):4516–4524. doi:10.1038/onc.2017.5528368416
   PubMed Web of Science ®Google Scholar
• Cesarini V, Guida E, Todaro F, et al. Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo. Oncogene. 2017;36(31):4508–4515. doi:10.1038/onc.2017.5328368402
   PubMed Web of Science ®Google Scholar
• Wang S, Tang L, Lin J, et al. ABCB5 promotes melanoma metastasis through enhancing NF-κB p65 protein stability. Biochem Biophys Res Commun. 2017;492(1):18–26. doi:10.1016/j.bbrc.2017.08.05228821433
   PubMed Web of Science ®Google Scholar
• Louphrasitthiphol P, Chauhan J, Goding CR. ABCB5 is activated by MITF and β-catenin and is associated with melanoma differentiation. Pigment Cell Melanoma Res. 2020;33(1):112–118. doi:10.1111/pcmr.1283031595650
   PubMed Web of Science ®Google Scholar
• Monzani E, Facchetti F, Galmozzi E, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 2007;43(5):935–946. doi:10.1016/j.ejca.2007.01.01717320377
   PubMed Web of Science ®Google Scholar
• Gunawan M, Venkatesan N, Loh JT, et al. The methyltransferase Ezh2 controls cell adhesion and migration through direct methylation of the extranuclear regulatory protein talin. Nat Immunol. 2015;16(5):505–516. doi:10.1038/ni.312525751747
   PubMed Web of Science ®Google Scholar
• Fisher ML, Adhikary G, Grun D, Kaetzel DM, Eckert RL. The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane. Mol Carcinog. 2016;55(12):2024–2036. doi:10.1002/mc.2244826693692
   PubMed Web of Science ®Google Scholar
• Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141(4):583–594. doi:10.1016/j.cell.2010.04.02020478252
   PubMed Web of Science ®Google Scholar
• Kumar SM, Liu S, Lu H, et al. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene. 2012;31(47):4898–4911. doi:10.1038/onc.2011.65622286766
   PubMed Web of Science ®Google Scholar
• Wickremesekera AC, Brasch HD, Lee VM, et al. Expression of cancer stem cell markers in metastatic melanoma to the brain. J Clin Neurosci. 2019;60:112–116. doi:10.1016/j.jocn.2018.10.06830626524
   PubMed Web of Science ®Google Scholar
• Doherty RE, Sisley K, Hammond DW, Rennie IG, Cross NA. Phenotypic plasticity in uveal melanoma is not restricted to a tumor subpopulation and is unrelated to cancer stem cell characteristics. Investig Ophthalmol Vis Sci. 2017;58(12):5387–5395. doi:10.1167/iovs.17-2227229049740
   PubMed Web of Science ®Google Scholar
• Jin Y, Zhang P, Wang Y, et al. Neddylation blockade diminishes hepatic metastasis by dampening cancer stem-like cells and angiogenesis in uveal melanoma. Clin Cancer Res. 2018;24(15):3741–3754. doi:10.1158/1078-0432.CCR-17-170329233905
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu M, Jin Y, Jiang S, Pan J. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor. Cancer Lett. 2017;400(April):47–60. doi:10.1016/j.canlet.2017.04.02828455241
   PubMedGoogle Scholar
• Zhou J, Jin B, Jin Y, Liu Y, Pan J. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo. Theranostics. 2017;7(6):1447–1462. doi:10.7150/thno.1745128529629
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu S, Ye Q, Pan J. Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma. Mol Cancer. 2019;18(1):140. doi:10.1186/s12943-019-1070-731526394
   PubMed Web of Science ®Google Scholar
• Rundle P. Treatment of posterior uveal melanoma with multi-dose photodynamic therapy. Br J Ophthalmol. 2014;98(4):494–497. doi:10.1136/bjophthalmol-2013-30443224463441
   PubMed Web of Science ®Google Scholar
• Ma YW, Liu YZ, Pan JX. Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation. Am J Cancer Res. 2016.
   Web of Science ®Google Scholar
• Quintana E, Shackleton M, Sabel MS, et al. Efficient tumour formation by single human melanoma cells. Nature. 2008;456(7222):593–598. doi:10.1038/nature0756719052619
   PubMed Web of Science ®Google Scholar
• Rambow F, Marine JC, Goding CR. Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. Genes Dev. 2019;33(19–20):1295–1318. doi:10.1101/gad.329771.11931575676
   PubMed Web of Science ®Google Scholar
• Fusi A, Reichelt U, Busse A, et al. Expression of the stem cell markers nestin and CD133 on circulating melanoma cells. J Invest Dermatol. 2011;131(2):487–494. doi:10.1038/jid.2010.28520882037
   PubMed Web of Science ®Google Scholar